1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hepatitis C Pricing and Reimbursement

Hepatitis C Pricing and Reimbursement

  • January 2015
  • -
  • Datamonitor Healthcare
  • -
  • 74 pages

The pricing and reimbursement of hepatitis C therapies has been in the spotlight since the launch of Sovaldi in the US in December 2013 at the price of $1,000 per pill. While Sovaldi's and Harvoni’s clinical effectiveness are undisputed, their high prices have prompted widespread criticism from payers, politicians, and patients due to the large budgetary impact of treating all eligible patients, which will exert a significant strain on healthcare systems.

This report addresses the following questions:
- What reimbursement restrictions have been imposed by US payers and how do they differ between major brands?
- Which payers have imposed patient prioritization and how do the strategies differ between countries?
- How are European payers controlling expenditure on hepatitis C drugs?
- In which markets did Sovaldi have the best outcome of the health technology assessment?

Table Of Contents

Hepatitis C Pricing and Reimbursement
EXECUTIVE SUMMARY
MARKET CONTEXT
1. The hepatitis C market is undergoing a seismic shift, 2. Budgetary impact of hepatitis C therapies is causing payer pushback, 3. Marketed hepatitis C products in the US, Japan, and five major EU markets, 4. Pipeline hepatitis C treatments in late-stage development, 5. Price assumptions, 6. Bibliography

US
7. Pricing, 8. Reimbursement, 9. Bibliography

JAPAN
10. Price premiums are awarded for added benefit or innovation, 11. Pricing of launched hepatitis C treatments, 12. Treatment guidelines have been changed in the light of recent approvals, 13. Bibliography

FIVE MAJOR EU MARKETS
14. Pricing, 15. Reimbursement and health technology assessment, 16. Bibliography

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025 Summary Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections ...

Global Market Study on Hepatitis C Treatment: Online Pharmacies Distribution Channel Segment Expected to Register the Fastest CAGR of 13.5% During 2016 - 2024

Global Market Study on Hepatitis C Treatment: Online Pharmacies Distribution Channel Segment Expected to Register the Fastest CAGR of 13.5% During 2016 - 2024

  • $ 4900
  • Industry report
  • November 2016
  • by Persistence Market Research

In this report, Persistence Market Research (PMR) offers an eight year forecast of the global hepatitis C treatment market between 2016 and 2024. The current study reveals the market trends and market ...

Liver Fibrosis Global Clinical Trials Review, H2, 2016

Liver Fibrosis Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • November 2016
  • by GlobalData

Liver Fibrosis Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Liver Fibrosis Global Clinical Trials Review, H2, 2016" provides an overview of Liver Fibrosis clinical ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.